The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

U.S. National Economic Council Director Kevin Hassett on Thursday dismissed the possibility of China retaliating to tariffs ...

Shares of Amgen Inc. AMGN rallied 1.36% to $309.85 Thursday, on what proved to be an all-around dismal trading session for ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

Based on Wall Street analyst estimates for 2025 EPS, Amgen trades at 15 times its projected earnings, while Merck sits at a ...

Amgen ( NASDAQ: NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

The FDA’s decision to grant Breakthrough Therapy Designation to UPLIZNA underscores the significant unmet medical need in ...